Immune checkpoint blockade (ICB) has changed the therapeutic landscape of oncology but its impact is limited by primary or secondary resistance. ICB resistance has been related to a lack of T cells infiltrating into the tumor. Strategies to overcome this hurdle have so far focused on the tumor microenvironment. but have mostly overlooked the role of tumor-draining lymph nodes (TDLN). https://www.pomyslnaszycie.com/vegetable-glycerin-sale/